METHODS: We addressed prognostic and risk of recurrence monitoring impacts associated with MIC+ cases. The electronic databases for literature and relevant articles were analysed.
RESULTS: Fifteen studies, (4882 patients), were included in our systematic review. While the results show that MICs significantly worsen prognosis in early CC. A tertiary prevention algorithm for low volume lymph node disease may stratify follow-up according to the burden of nodal disease and provide data that helps improve follow-up performance.
CONCLUSIONS: MICs worsen prognosis and should be managed as suggested by the algorithm. However, this algorithm must be externally validated. The clinical impact of isolated tumor cells (ITC) remains unclear.
方法:我们讨论了与MIC+病例相关的预后和复发监测风险。对文献和相关文章的电子数据库进行了分析。
结果:15项研究,(4882名患者),包括在我们的系统审查中。而结果表明,MIC显著恶化早期CC的预后。低容量淋巴结疾病的三级预防算法可以根据淋巴结疾病的负担对随访进行分层,并提供有助于提高随访绩效的数据。
结论:MIC使预后恶化,应按照算法建议进行管理。然而,此算法必须进行外部验证。分离的肿瘤细胞(ITC)的临床影响尚不清楚。